Sub menu

 
 

ERLOTINIB SANDOZ (Sandoz Pty Ltd)

Product name
ERLOTINIB SANDOZ
Sponsor
Sandoz Pty Ltd
Date registered
Evaluation commenced
Decision date
Approval time
121 working days (255)
Active ingredients
erlotinib hydrochloride
Registration type
New generic medicine
Indication
Non-small cell lung cancer

ERLOTINIB SANDOZ (film coated tablet) is indicated for the first-line treatment of patients with advanced (Stage IIIB) or metastatic (Stage IV) non-small cell lung cancer (NSCLC) with activating EGFR mutations.

ERLOTINIB SANDOZ is indicated for maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutations who have not progressed on first-line chemotherapy.

ERLOTINIB SANDOZ is also indicated for the treatment of patients with locally advanced or metastatic non- small cell lung cancer after failure of prior chemotherapy.

Pancreatic cancer

ERLOTINIB SANDOZ in combination with gemcitabine is indicated for the treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer.

Help us improve the Therapeutic Goods Administration site